Source: Rezolute, Inc. 2/13/2024
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the second quarter of fiscal 2024 ended December 31, 2023, and provided an update on recent business developments and outlook.
“2024 is an exciting year of execution and milestones across our pipeline, with RZ358 continuing to demonstrate benefit to patients with hypoglycemia resulting from varying causes of hyperinsulinism, and in different indications,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “We recently initiated sunRIZE, a global, pivotal, Phase 3 clinical study in patients with congenital hyperinsulinism, and we also continue to see favorable outcomes from our Expanded Access Program with RZ358, in patients with tumor-associated hyperinsulinism caused by insulinomas, for which we are evaluating a potential development program. Additionally, we completed enrollment in the Phase 2 study of RZ402 in patients with diabetic macular edema and look forward to reporting topline data from that program in the second quarter of 2024.”
Clinical and Regulatory Highlights
RZ358 is a monoclonal antibody for the treatment of hyperinsulinism.
- cHI
- Rezolute
initiated sunRIZE, a global, pivotal, Phase 3 clinical study in
participants with cHI, in Europe and other geographies outside of the
U.S.
- Topline results expected mid-2025.
- Innovation
and Licensing Application Passport (ILAP) designation awarded to RZ358
for the treatment of cHI by the U.K. Medicines and Healthcare products
Regulatory Agency (MHRA).
- Designation was granted based on the recognition of substantial unmet medical need in this condition and the potential benefit to patients as evidenced by the Phase 2b RIZE study results in cHI, which safely demonstrated significant improvements in hypoglycemia.
- Supplements analogous PRIME designation status already granted by the European Medicines Agency (EMA) in E.U.
- Rezolute
initiated sunRIZE, a global, pivotal, Phase 3 clinical study in
participants with cHI, in Europe and other geographies outside of the
U.S.
- taHI
- RZ358 has been shown to counteract excessive insulin action downstream, at the insulin-receptor on target organs. The unique mechanism of action of RZ358 makes the therapy a potential universal treatment for hypoglycemia resulting from any cause of hyperinsulinism, including neuroendocrine tumors (insulinomas).
- Given the unmet need in taHI and the potential therapeutic benefit of RZ358 as demonstrated in the individual case reports from the EAP, the Company met with FDA in January 2024 (January Meeting) and received a favorable opinion from the Agency on the feasibility of RZ358 being studied in a late-stage clinical trial as a new development program and second rare disease indication for RZ358.
- In the January Meeting, FDA indicated that current dose caps on cHI studies would not be applicable to taHI studies. Therefore, considering the indication is primarily adult, current partial clinical holds pertaining to cHI studies would be largely irrelevant in taHI.
- The
Company remains engaged with FDA in the attempt to resolve ongoing
partial clinical holds on clinical studies in the cHI indication.
RZ402 is a selective and potent oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME).
- Completed enrollment in Phase 2 U.S., multi-center, randomized, double-masked, placebo-controlled, parallel-arm study evaluating the safety, efficacy, and pharmacokinetics of RZ402 administered as an oral monotherapy over a 12-week treatment period in participants with DME who are naïve to or have received limited anti-VEGF injections.
- Topline results expected in the second quarter of 2024.
Corporate Highlights
- Expanded leadership team with appointment of Daron Evans, M.S., M.B.A, as Chief Financial Officer.
- Mr. Evans has substantial experience leading public and private life science companies, with expertise in corporate finance, capital markets, and strategic transactions. He will help shepherd Rezolute through its next chapter in late-stage development.
Second Quarter Fiscal 2024 Financial Results
- Cash,
cash equivalents and investments in marketable debt securities totaled
$96.0 million as of December 31, 2023, compared to $118.4 million as of
June 30, 2023
- Research and
development expenses were $12.0 million for the second quarter of fiscal
2024, compared to $10.9 million for the same period in fiscal 2023,
with the increase primarily attributable to increased expenditures in
clinical trial activities and manufacturing costs
- General
and administrative expenses were $3.2 million for the second quarter of
fiscal 2024, compared to $3.4 million for the same period in fiscal
2023, with the decrease primarily attributable to lower
personnel-related expenses
- Net loss was $13.9 million for the second quarter of fiscal 2024, compared to $13.6 million for the same period in fiscal 2023
Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, treating physicians, and the healthcare system. Rezolute is steadfast in its mission to create profound, positive, and lasting impacts on patients’ lives. Patient, clinician, and advocate voices are integrated in the Company’s drug development process. Rezolute places an emphasis on understanding the patient’s lived experiences, enabling the Company to boldly address a range of severe conditions.
No comments:
Post a Comment